Business
VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales
Veteran business development leader with deep expertise in human-relevant NAM and spheroid-based in vitro services to spearhead commercial growth along the US East Coast, deepening VivoSim’s reach with biopharma innovators seeking human-relevant liver and GI toxicity solutionsSAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced the appoi
About this update from Vivosim Labs, Inc.
[{"type":"image","alt":"VivoSim Labs, Inc.","displaySize":"","headline":null,"caption":"VivoSim Labs, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":133,"url":"https://media.zenfs.com/en/globenewswire.com/e54b5ed2b47b2a40c4e408056374d68a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3k1uNndpaNI76.ORZ8sOyw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e54b5ed2b47b2a40c4e408056374d68a","width":300,"height":133}},"lazy":false},{"type":"text","content":"Veteran business development leader with deep expertise in human-relevant NAM and spheroid-based in vitro services to spearhead commercial growth along the US East Coast, deepening VivoSim’s reach with biopharma innovators seeking human-relevant liver and GI toxicity solutions","length":277,"tagName":"p"},{"type":"text","content":"SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced the appointment of Dr. Arumugham (Ragoo) Raghunathan, PhD as Vice President of Global Sales. Based in the Greater Boston area, Dr. Raghunathan will lead commercial expansion and secure strategic partnerships with biopharma innovators, established pharmaceutical companies, CROs/CDMOs, and research institutions. His focus will be on delivering VivoSim’s liver and gastrointestinal (GI) toxicity solutions for earlier de-risking of drug candidates and clearer feasibility decisions throughout the development process.","length":730,"tagName":"p"},{"type":"text","content":"A seasoned executive, Dr. Raghunathan brings extensive experience building trusted, consultative relationships across drug discovery and advanced in vitro biology. He is recognized for bridging scientific and commercial stakeholders, structuring collaborative programs, and guiding customers from pilot studies to scaled deployments—particularly in complex, high-stakes areas such as safety assessment and translational decision-making.","length":436,"tagName":"p"},{"type":"text","content":"“Ragoo builds and strengthens relationships through scientific rigor and a relentless emphasis on outcomes,” said Tony Lialin, Chief Commercial Officer of VivoSim. “He is the kind of leader customers instantly trust and recognize a...